PMC:7408073 / 86415-86879 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T483","span":{"begin":40,"end":45},"obj":"Body_part"},{"id":"T484","span":{"begin":191,"end":207},"obj":"Body_part"},{"id":"T485","span":{"begin":202,"end":207},"obj":"Body_part"},{"id":"T486","span":{"begin":457,"end":463},"obj":"Body_part"}],"attributes":[{"id":"A483","pred":"fma_id","subj":"T483","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A484","pred":"fma_id","subj":"T484","obj":"http://purl.org/sig/ont/fma/fma67653"},{"id":"A485","pred":"fma_id","subj":"T485","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A486","pred":"fma_id","subj":"T486","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"For example, Ang (1–7) concentration in blood by ACE2 pathway upregulation is dependent both on the increase of the (antagonistic) Ang II (and its precursor, Ang I) and on MasR expression on surface of cells in the organs. To this regard, the detection of inactive metabolites, such as bradykinin (1–7), in COVID-19 patients and comparison with its concentration in healthy subjects could be the most indicative and reliable markers of ACE2 activity in the plasma."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T168","span":{"begin":40,"end":45},"obj":"Body_part"},{"id":"T169","span":{"begin":215,"end":221},"obj":"Body_part"}],"attributes":[{"id":"A168","pred":"uberon_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A169","pred":"uberon_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"For example, Ang (1–7) concentration in blood by ACE2 pathway upregulation is dependent both on the increase of the (antagonistic) Ang II (and its precursor, Ang I) and on MasR expression on surface of cells in the organs. To this regard, the detection of inactive metabolites, such as bradykinin (1–7), in COVID-19 patients and comparison with its concentration in healthy subjects could be the most indicative and reliable markers of ACE2 activity in the plasma."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2984","span":{"begin":49,"end":53},"obj":"Gene"},{"id":"2985","span":{"begin":172,"end":176},"obj":"Gene"},{"id":"2986","span":{"begin":286,"end":296},"obj":"Gene"},{"id":"2987","span":{"begin":436,"end":440},"obj":"Gene"},{"id":"2988","span":{"begin":13,"end":21},"obj":"Gene"},{"id":"2989","span":{"begin":316,"end":324},"obj":"Species"},{"id":"2990","span":{"begin":131,"end":137},"obj":"Gene"},{"id":"2991","span":{"begin":307,"end":315},"obj":"Disease"}],"attributes":[{"id":"A2984","pred":"tao:has_database_id","subj":"2984","obj":"Gene:59272"},{"id":"A2985","pred":"tao:has_database_id","subj":"2985","obj":"Gene:116511"},{"id":"A2986","pred":"tao:has_database_id","subj":"2986","obj":"Gene:3827"},{"id":"A2987","pred":"tao:has_database_id","subj":"2987","obj":"Gene:59272"},{"id":"A2988","pred":"tao:has_database_id","subj":"2988","obj":"Gene:284"},{"id":"A2989","pred":"tao:has_database_id","subj":"2989","obj":"Tax:9606"},{"id":"A2990","pred":"tao:has_database_id","subj":"2990","obj":"Gene:24179"},{"id":"A2991","pred":"tao:has_database_id","subj":"2991","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For example, Ang (1–7) concentration in blood by ACE2 pathway upregulation is dependent both on the increase of the (antagonistic) Ang II (and its precursor, Ang I) and on MasR expression on surface of cells in the organs. To this regard, the detection of inactive metabolites, such as bradykinin (1–7), in COVID-19 patients and comparison with its concentration in healthy subjects could be the most indicative and reliable markers of ACE2 activity in the plasma."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T494","span":{"begin":307,"end":315},"obj":"Disease"}],"attributes":[{"id":"A494","pred":"mondo_id","subj":"T494","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"For example, Ang (1–7) concentration in blood by ACE2 pathway upregulation is dependent both on the increase of the (antagonistic) Ang II (and its precursor, Ang I) and on MasR expression on surface of cells in the organs. To this regard, the detection of inactive metabolites, such as bradykinin (1–7), in COVID-19 patients and comparison with its concentration in healthy subjects could be the most indicative and reliable markers of ACE2 activity in the plasma."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1035","span":{"begin":40,"end":45},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T1036","span":{"begin":40,"end":45},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T1037","span":{"begin":202,"end":207},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T1038","span":{"begin":215,"end":221},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T1039","span":{"begin":441,"end":449},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1040","span":{"begin":457,"end":463},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"For example, Ang (1–7) concentration in blood by ACE2 pathway upregulation is dependent both on the increase of the (antagonistic) Ang II (and its precursor, Ang I) and on MasR expression on surface of cells in the organs. To this regard, the detection of inactive metabolites, such as bradykinin (1–7), in COVID-19 patients and comparison with its concentration in healthy subjects could be the most indicative and reliable markers of ACE2 activity in the plasma."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T52995","span":{"begin":135,"end":137},"obj":"Chemical"},{"id":"T40147","span":{"begin":265,"end":276},"obj":"Chemical"},{"id":"T54329","span":{"begin":286,"end":296},"obj":"Chemical"}],"attributes":[{"id":"A42084","pred":"chebi_id","subj":"T52995","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A1101","pred":"chebi_id","subj":"T40147","obj":"http://purl.obolibrary.org/obo/CHEBI_25212"},{"id":"A64187","pred":"chebi_id","subj":"T54329","obj":"http://purl.obolibrary.org/obo/CHEBI_3165"}],"text":"For example, Ang (1–7) concentration in blood by ACE2 pathway upregulation is dependent both on the increase of the (antagonistic) Ang II (and its precursor, Ang I) and on MasR expression on surface of cells in the organs. To this regard, the detection of inactive metabolites, such as bradykinin (1–7), in COVID-19 patients and comparison with its concentration in healthy subjects could be the most indicative and reliable markers of ACE2 activity in the plasma."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T154","span":{"begin":243,"end":264},"obj":"http://purl.obolibrary.org/obo/GO_0014863"}],"text":"For example, Ang (1–7) concentration in blood by ACE2 pathway upregulation is dependent both on the increase of the (antagonistic) Ang II (and its precursor, Ang I) and on MasR expression on surface of cells in the organs. To this regard, the detection of inactive metabolites, such as bradykinin (1–7), in COVID-19 patients and comparison with its concentration in healthy subjects could be the most indicative and reliable markers of ACE2 activity in the plasma."}

{"project":"LitCovid-sentences","denotations":[{"id":"T422","span":{"begin":0,"end":222},"obj":"Sentence"},{"id":"T423","span":{"begin":223,"end":464},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For example, Ang (1–7) concentration in blood by ACE2 pathway upregulation is dependent both on the increase of the (antagonistic) Ang II (and its precursor, Ang I) and on MasR expression on surface of cells in the organs. To this regard, the detection of inactive metabolites, such as bradykinin (1–7), in COVID-19 patients and comparison with its concentration in healthy subjects could be the most indicative and reliable markers of ACE2 activity in the plasma."}